N-(5-benzyl-1,3-thiazol-2-yl)-3-(2-hydroxyethoxy)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-benzyl-1,3-thiazol-2-yl)-3-(2-hydroxyethoxy)benzamide
• 化学式: C₁₉H₁₈N₂O₃S
• 分子量: 354.4
• InChiKey: ZHOFNALLEOAVIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  99.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
  申请人：MacRegen, Inc.

  公开号：US10905770B2

  公开（公告）日：2021-02-02

  The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin). In some embodiments, the one or more therapeutic agents are mixed with, non-covalently associated with or covalently bonded to a cell-penetrating peptide (CPP), encapsulated in CPP-conjugated nanoparticles, micelles or liposomes, or modified (e.g., stapled, prenylated, lipidated or coupled to a small-molecule α-helix mimic) to acquire membrane-translocating ability. In certain embodiments, the one or more therapeutic agents are administered by eye drop.

  本公开提供了用于治疗老年性黄斑变性（AMD）和其他眼部疾病的治疗剂。一种或多种治疗剂可用于治疗AMD的任何阶段（包括早期、中期和晚期），以及AMD的任何表型，包括地理萎缩（包括非中心性GA和中心性GA）和新生血管（包括1型、2型和3型NV）。在某些实施方案中，一种或多种治疗剂是或包括抗血脂异常剂、抗氧化剂、抗炎剂、补体抑制剂、神经保护剂或抗血管生成剂，或它们的任意组合。在某些实施方案中，一种或多种治疗剂是或包括抗血脂异常剂（例如，载脂蛋白模拟物或/和他汀类药物）。在某些实施方案中，一种或多种治疗剂与细胞穿透肽（CPP）混合、非共价结合或共价键合，包封在CPP共轭的纳米颗粒、胶束或脂质体中，或进行修饰（例如，钉合、前酰化、脂质化或与小分子α-螺旋模拟物偶联）以获得膜转运能力。在某些实施方案中，一种或多种治疗剂通过滴眼液给药。
• TOPICAL DELIVERY OF THERAPEUTIC AGENTS COMPRISING CELL-PENETRATING PEPTIDES FOR USE FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES
  申请人：Roizman, Keith

  公开号：EP3654941A1

  公开（公告）日：2020-05-27
• TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS
  申请人：MacRegen, Inc.

  公开号：US20180296525A1

  公开（公告）日：2018-10-18

  The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In certain embodiments, an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic and/or a statin) is used alone to treat or slow the progression of atrophic AMD (including early AMD and intermediate AMD), and/or to prevent or delay the onset of AMD, advanced AMD and/or neovascular AMD. In further embodiments, two or more therapeutic agents (e.g., any combinations of an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector and an anti-angiogenic agent) that target multiple underlying factors of AMD (e.g., formation of lipid-rich deposits, oxidative stress, local inflammation, cell death and neovascularization) are used to treat or slow the progression of atrophic AMD (including non-central GA and central GA) or neovascular AMD (including types 1, 2 and 3 NV), and/or to prevent or delay the onset of AMD, advanced AMD and/or neovascular AMD.
• TOPICAL DELIVERY OF THERAPEUTIC AGENTS USING CELL-PENETRATING PEPTIDES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES
  申请人：Macregen, Inc.

  公开号：US20190015521A1

  公开（公告）日：2019-01-17

  The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin). In some embodiments, the one or more therapeutic agents are mixed with, non-covalently associated with or covalently bonded to a cell-penetrating peptide (CPP), encapsulated in CPP-conjugated nanoparticles, micelles or liposomes, or modified (e.g., stapled, prenylated, lipidated or coupled to a small-molecule α-helix mimic) to acquire membrane-translocating ability. In certain embodiments, the one or more therapeutic agents are administered by eye drop.
• [EN] METHODS AND KITS FOR THE PROGNOSIS OF COLORECTAL CANCER<br/>[ES] MÉTODOS Y KITS PARA EL PRONÓSTICO DEL CÁNCER COLORRECTAL<br/>[FR] MÉTHODES ET KITS POUR LE PRONOSTIC DU CANCER COLORECTAL
  申请人：FUNDACIÓN IMDEA ALIMENTACIÓN

  公开号：WO2014091048A1

  公开（公告）日：2014-06-19

  La invención se refiere a los métodos para predecir el riesgo de recaída de los pacientes con cáncer colorrectal, así como a los métodos para proporcionar medicina personalizada a dichos pacientes, basándose en los niveles de expresión de los genes ACSL1, ACSL4, GCNT3, LPL, APOC1y SCD, cuyos productos de expresión están implicados en el metabolismo energético celular. La invención también se refiere a los kits para llevar a cabo los métodos predictivos y de medicina predictiva.